First-in-human exploratory trial assessing safety, feasibility, and efficacy of artificial protein (silk-elastin) in promoting healing in patients with meniscus injuries

被引:0
|
作者
Ishikawa, Masakazu [1 ,2 ,5 ]
Tsuji, Shunya [2 ]
Kamei, Goki [2 ]
Nakata, Kyohei [2 ]
Nekomoto, Akinori [2 ]
Hashiguchi, Naofumi [2 ]
Nakasa, Tomoyuki [2 ]
Nakamae, Atsuo [2 ]
Kamei, Naosuke [2 ]
Inoue, Keiichiro [3 ]
Kawabata, Shingo [3 ]
Ueda, Keiko [4 ]
Adachi, Nobuo [2 ]
机构
[1] Kagawa Univ, Fac Med, Dept Orthoped Surg, Takamatsu, Kagawa, Japan
[2] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Orthoped Surg, Hiroshima, Japan
[3] Sanyo Chem Ind, Kyoto, Japan
[4] Trarnslat Res Ctr Med Innovat, Kobe, Hyogo, Japan
[5] Kagawa Univ, Fac Med, Dept Orthoped Surg, 1750-1 Ikenobe,Miki Cho, Takamatsu, Kagawa 7610793, Japan
来源
SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期
关键词
Meniscus tear; Arthroscopic meniscus repair; Artificial protein; Silk-elastin; Needle arthroscope; Knee osteoarthritis; PLATELET-RICH PLASMA; ARTHROSCOPIC EVALUATION; NEEDLE ARTHROSCOPY; LATERAL MENISCUS; REPAIR; TEARS; AUGMENTATION; KNEES; COST;
D O I
10.1038/s41598-025-88616-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Meniscal tears, especially those in avascular regions, pose a significant risk for osteoarthritis if repair fails. While meniscal repair is the preferred method for preserving knee function, it often has a high failure rate in avascular zones. This study aimed to evaluate the safety and potential efficacy of silk-elastin (SE), an artificial protein with wound-healing properties, for enhancing meniscal repair. Eight patients with meniscal tears in avascular areas underwent arthroscopic repair followed by SE application, including cases of lateral and medial tears, discoid lateral meniscus, and bucket-handle tears. No adverse events or reactions were attributed to SE. At 3 months post-surgery, clinical outcomes and repair sites were evaluated using MRI and arthroscopy. Significant improvements were observed in Lysholm and visual analog scale scores (P < 0.05), with the knee injury and osteoarthritis outcome scores showing significant improvement in the symptom subscale. MRI findings indicated one patient with grade 1 healing, three with grade 2, and four with grade 3 (unhealed). Arthroscopically, six patients demonstrated completely healed menisci, while two showed incomplete healing; none were classified as "unhealed." These findings suggest that SE is safe and may support meniscal healing in avascular zones, indicating its potential to improve repair outcomes.
引用
收藏
页数:13
相关论文
共 29 条
  • [21] AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients
    Jung, Susanne
    Nelde, Annika
    Maringer, Yacine
    Denk, Monika
    Zieschang, Lisa
    Kammer, Christine
    Oezbek, Melek
    Martus, Peter
    Hackenbruch, Christopher
    Englisch, Alexander
    Heitmann, Jonas S.
    Salih, Helmut R.
    Walz, Juliane S.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [22] Evaluation of safety, feasibility and efficacy of intra-ovarian transplantation of autologous adipose derived mesenchymal stromal cells in idiopathic premature ovarian failure patients: non-randomized clinical trial, phase I, first in human
    Mashayekhi, M.
    Mirzadeh, E.
    Chekini, Z.
    Ahmadi, F.
    Eftekhari-Yazdi, P.
    Vesali, S.
    Madani, T.
    Aghdami, N.
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [23] Evaluation of safety, feasibility and efficacy of intra-ovarian transplantation of autologous adipose derived mesenchymal stromal cells in idiopathic premature ovarian failure patients: non-randomized clinical trial, phase I, first in human
    M. Mashayekhi
    E. Mirzadeh
    Z. Chekini
    F. Ahmadi
    P. Eftekhari-Yazdi
    S. Vesali
    T. Madani
    N. Aghdami
    Journal of Ovarian Research, 14
  • [24] LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer
    Forde, P. M.
    Atmaca, A.
    Brueck, P.
    Munshi, N.
    Kaczorowska, M. A.
    Schell, T.
    Tuereci, Oe.
    Sahin, U.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1095 - S1095
  • [25] TFX06, a nextgeneration oral CERAN/SERD, shows favorable safety and PK profile, extracranial and intracranial efficacy in patients with ER+/HER2-breast cancer: Preliminary results from a phase 1/2 first-in-human trial
    Fu, Zhaojian
    Zhang, Zhiye
    Song, Jia
    Chen, Yang
    Fang, Douglas
    Sha, Wei
    Zhang, Jian
    Ding, Charles
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes.
    Park, John J.
    Lee, Keun Wook
    Oh, Do-Youn
    Sabanathan, Dhanusha
    Kim, Se Hyun
    Kim, Tae Min
    Kim, Myungsuk
    Yoon, Jaebong
    Lee, Hyunmi
    Kim, Boram
    Ko, Yunjung
    Jeon, Eunyoung
    Cheon, Seonghye
    Shim, Eunyoung
    Park, Bum-Chan
    Lee, Han Seung
    Park, Seongyeol
    Paeng, Kyunghyun
    Ock, Chan-Young
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease-positive pancreatic and colorectal cancer
    Devoe, Craig E.
    Pant, Shubham
    Wainberg, Zev A.
    Chung, Vincent
    George, Thomas J.
    Kasi, Pashtoon Murtaza
    VanWyk, Haley
    Tavares, Amy
    Perry, James
    Kheoh, Thian
    McNeil, Lisa
    Welkowsky, Esther
    DeMuth, Peter
    Haqq, Christopher M.
    O'Reilly, Eileen M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D-or G12R-mutated pancreatic and colorectal cancer
    O'Reilly, Eileen Mary
    Wainberg, Zev A.
    Weekes, Colin D.
    Furqan, Muhammad
    Kasi, Pashtoon Murtaza
    Devoe, Craig E.
    Leal, Alexis Diane
    Chung, Vincent
    Perry, James
    Seenappa, Lochana
    McNeil, Lisa
    Welkowsky, Esther
    DeMuth, Peter
    Haqq, Christopher M.
    Pant, Shubham
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors
    Luen, S. J.
    Ahern, E. S.
    Berger, C.
    Desai, J.
    Frentzas, S.
    Gan, H.
    Gualandi, M.
    Markman, B.
    Millward, M.
    Rafiei, A.
    Tran, B.
    Renner, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S494 - S494